Results 171 to 180 of about 119,651 (301)

Histopathological stratification of primary aldosteronism using the CYP11B2 size ratio: first evaluation in clinical routine

Histopathology, EarlyView.
CYP11B2 immunohistochemistry identifies aldosterone‐producing nodules and enables objective subtyping using the B2 ratio (B2R), defined as the size ratio between the largest and second‐largest CYP11B2‐positive nodules. A B2R ≥8.1 indicates classical histology with a dominant lesion and high likelihood of cure, whereas B2R <8.1 reflects non‐classical ...
Adam Stenman, Tim Nilsson, Henrik Falhammar, C. Christofer Juhlin   +3 more
wiley   +1 more source

Clinical and Biochemical Features Associated with Coexisting Primary Aldosteronism in Patients with Obstructive Sleep Apnea: A Cross-Sectional Study. [PDF]

Diagnostics (Basel)
Li M, Chen X, Zhang Y, Teng Y, Huang B, Tan M, Liu Z, Guo M, Li C, Su X, Jiang T, Wang M.   +11 more
europepmc   +1 more source

Hypertension among people living with HIV (PLHIV) compared with people without HIV (PWoH): A systematic review with meta‐analysis

HIV Medicine, EarlyView.
Abstract Introduction Hypertension is a major cardiovascular risk factor and has increased among people living with HIV. However, evidence on its association with HIV status remains inconsistent. This systematic review aimed to assess the association between HIV status and hypertension and to examine, through subgroup analyses, whether this association
Mariene Garcia Gomes, Kássio Silva Cunha, Erika Cardoso Abud Parreira, Caroline Becker, Geórgia das Graças Pena, Sinara Laurini Rossato   +5 more
wiley   +1 more source

Improving primary aldosteronism diagnosis and treatment: outcomes from an endocrine hypertension service

Internal Medicine Journal, EarlyView.
Abstract Aims To evaluate the sustained impact of the Endocrine Hypertension Service on primary aldosteronism (PA) diagnosis and management over a subsequent 3‐year period. Background PA is a prevalent yet underdiagnosed cause of secondary hypertension, associated with increased cardiovascular, renal and metabolic risk. Limited awareness, resources and
Minn W. Chow, Chrislyn Ng, Jimmy Shen, Peter J. Fuller, Jun Yang, Renata Libianto   +5 more
wiley   +1 more source

At the heart of home‐based care: multidisciplinary heart failure management in a quaternary centre's community programmes

Internal Medicine Journal, EarlyView.
Abstract Background Heart failure (HF) is a frequent cause of hospital admissions, carrying a high risk of hospital readmission and mortality. Alfred Health General Medicine Hospital in the Home (GM‐HITH) and Hospital Admission Risk Program (HARP) offer multidisciplinary HF care to multimorbid patients in bed‐substitution and non‐admitted community ...
Elana Forbes, Ingrid Hopper, Cathy Corbett, Felice Borghmans, Emma O'Donnell, Ana Slavnic, Genevieve Harvey, Elizabeth Rochford, Archana Thayaparan   +8 more
wiley   +1 more source

Unrecognized primary aldosteronism may confound outcomes in adrenal Cushing's syndrome. [PDF]

Ther Adv Endocrinol Metab
Qin Y, Hong S.
europepmc   +1 more source

Plasma Aldosterone Levels in Primary Aldosteronism

Folia Endocrinologica Japonica, 1973
FUKUCHI, Soitsu, TAKENOUCHI, Takahiko, NAKAJIMA, Katsuo, SASAKI, Chikashi   +3 more
openaire   +3 more sources

Cardiovascular preventive role of thiazolidinedione in patients with type 2 diabetes mellitus undergoing percutaneous coronary intervention

Journal of Diabetes Investigation, EarlyView.
Among patients with type 2 diabetes undergoing percutaneous coronary intervention, thiazolidinedione use was independently associated with a significantly reduced risk of a composite of myocardial infarction, stroke, and all‐cause death, notably without an increased risk of admission for heart failure. ABSTRACT Background Thiazolidinediones (TZD) are a
Jinkwon Kim, Jimin Jeon, Joonsang Yoo, Minyoul Baik, Seok‐Jae Heo, Ji Woong Roh   +5 more
wiley   +1 more source

Primary Aldosteronism Subtype Diagnosis: Adrenal Venous Sampling vs. CXCR4 PET CT. [PDF]

Endocrinol Diabetes Metab
Liu S, Zhang Y, Liu X, Zhou H, Shen S, Yin N, Zhu Y.   +6 more
europepmc   +1 more source

Comparison between liraglutide and dulaglutide on the incidence or progression of eye and kidney complications

Journal of Diabetes Investigation, EarlyView.
We conducted the single‐center, retrospective cohort study to evaluate and compare the risk of diabetic eye and kidney complications between newly initiated once‐daily liraglutide (0.9 mg) and once‐weekly dulaglutide (0.75 mg) in 331 Japanese patients with type 2 diabetes.
Aki Katamine, Junko Oya, Yuichiro Kondo, Yukiko Hasegawa, Tomoko Nakagami   +4 more
wiley   +1 more source